Finance

Beta
Lists
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
$15.23
+3.18%
(+0.47) 1D
$15.30
+0.46% (+0.070)
After hours
Closed: Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
$14.78
High
$15.50
Low
$14.58
Mkt. cap
1.28B
Avg. vol.
1.60M
Volume
1.32M
52-wk high
$26.95
52-wk low
$3.79
EPS
-$0.53
Beta
0.82
Shares outstanding
84.09M
No. of employees
37
Open
$14.78
High
$15.50
Low
$14.58
Mkt. cap
1.28B
Avg. vol.
1.60M
Volume
1.32M
52-wk high
$26.95
52-wk low
$3.79
EPS
-$0.53
Beta
0.82
Shares outstanding
84.09M
No. of employees
37
News stories
From sources across the web
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorBiotechnology
Websitecorvuspharma.com
Analyst ratings
Based on 5 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current $15.23
$40.00 (+162.64%)
Average
$31.60 (+107.49%)
Lowest
$27.00 (+77.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$30.00
+97%
06/12/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$33.00
+116.7%
05/15/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$40.00
+162.6%
05/14/2026
Sean Lee CFA
H.C. Wainwright
Buy
Reiterated
$27.00
+77.3%
05/15/2026
Etzer Darout
Barclays
Buy
Maintained
$28.00
+83.8%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.87M
8.45M
9.94M
11.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.39M
2.12M
2.28M
3.70M
Operating expense
10.26M
10.57M
12.22M
14.88M
Total operating expenses
10.26M
10.57M
12.22M
14.88M
Operating income
-10.26M
-10.57M
-12.22M
-14.88M
Other non operating income
2.01M
-
-
-
EBT including unusual items
-8.00M
-10.16M
-12.32M
-13.69M
EBT excluding unusual items
-8.00M
-10.16M
-12.32M
-13.69M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.00M
-10.16M
-12.32M
-13.69M
Net profit margin
-
-
-
-
Earnings per share
-0.13
-0.12
-0.15
-0.15
Interest and investment income
639.00K
738.00K
603.00K
1.78M
Interest expense
-
-
-
-
Net interest expenses
639.00K
738.00K
603.00K
1.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.23M
-10.54M
-12.19M
-14.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer